Agency for Science, Technology and Research

National University of Singapore

Kuwait University

Jean Paul Thiery

Milad S Bitar

Fahd Al-Mulla

Kian Ngiap Chua

Jayantha Gunaratne

Yun-Ju Ruby Huang

Prashant Kumar

Wen Jing Sim

Seiichi Mori

Disclosed are bladder cancer protein biomarkers, methods of determining whether a patient suffers from or shows recurrence of bladder cancer or early stage bladder cancer, or late stage bladder cancer using the bladder cancer protein biomarkers, a detection system, and kits thereof. Said bladder cancer biomarkers comprise at least one of Coronin-IA, Apolipoprotein A-IV, Semenogelin-2, Gamma-synuclein and DJ-1, and variants thereof.

Bladder carcinoma biomarkers

The method for determining risk of metastatic relapse in a patient diagnosed with colorectal cancer (CRC) can include detecting a level of at least one indicator of metastatic potential in a biological sample from the patient, comparing the level of the indicator of metastatic potential with a control, and identifying the patient as one who is at risk of metastatic relapse and a candidate for chemotherapy if an aberrant level of the indicator of metastatic potential in the biological sample compared to the control is detected. The at least one indicator of metastatic potential can include at least one metastasis-inducing gene and/or at least one metastasis suppressor gene. An aberrant level of the at least one indicator of metastatic potential can include a copy number gain of the metastasis-inducing gene and/or a copy number loss of the metastasis-suppressor gene.

Method for determining risk of metastatic relapse in a patient diagnosed with colorectal cancer

In a first aspect the present invention is directed to a method of generating a scheme allowing classification of a cancer of an individual patient for estimating a clinical outcome for said patient. It also refers to a method of estimating a clinical outcome of a patient suffering from epithelial ovarian cancer (EOC). The present invention also refers to a method of determining whether the epithelial mesenchymal score of a patient suffering from a cancer can be changed by administering an EMT reversal agent to increase patients susceptibility for an anti-cancer treatment.

Patient stratification and determining clinical outcome for cancer patients

Growing community of inventors

Singapore, Singapore

Jean Paul Thiery